Aqueous composition containing epinastine or its salt
By adding an appropriate amount of quaternary ammonium compound to the eye drops, the migration of epistein or its salt to the eye tissue is improved, and the problem of degradation of traditional Chinese medicine in the prior art is solved, and a more efficient eye drop effect is achieved.
Patent Information
- Application Number
- CN202180026833.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-16
- Filing Date
- 2021-04-15
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-04-15
AI Technical Summary
In the case of reducing the use of benzalkonium chloride, existing eye drops are difficult to effectively improve the migration of epistin or its salt to the eye tissue, resulting in a decrease in drug efficacy.
The migration of its tolerant to the eye tissue is improved by adding a specific amount of quaternary ammonium compounds, such as benzalkonium chloride, to the aqueous composition as eye drops of epistin or its salt.
It significantly improves the migration amount and efficacy of epistin or its salt in the eye tissue, and avoids the risk of corneal epithelial damage caused by excessive use of benzalkonium chloride.
Smart Images

Figure BDA0003872042980000051 
Figure BDA0003872042980000141 
Figure BDA0003872042980000142
Abstract
Description
Technical Field
[0001] The present invention relates to an aqueous composition containing epinastine or a salt thereof, and more specifically, to an aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound (hereinafter also referred to as "the aqueous composition of the present invention"). Background Art
[0002] In order to prevent the growth of fungi, etc., it is considered that the aqueous composition containing water and other solvents that are used repeatedly requires more than a certain amount of antiseptic measures. Therefore, a preservative is usually added to such a composition. For example, benzalkonium chloride is commonly used in eye drops. Benzalkonium chloride is water-soluble, chemically stable, and has a higher antiseptic effect than other preservatives. However, benzalkonium chloride is cell-damaging, and if the exposure amount increases, the possibility of causing corneal epithelial damage increases, so it is hoped that it will not be used as much as possible.
[0003] Alesion, currently available in Japan (注册商标) The eye drops 0.05% are eye drops containing epinastine hydrochloride as an active ingredient, but benzalkonium chloride is not added as an additive, but boric acid is added instead (Non-Patent Document 1).
[0004] It is also known that a sufficient antiseptic effect can be obtained without substantially containing a preservative or a component having an antiseptic effect by setting the concentration of epinastine or a salt thereof in the eye drops to more than 0.075% (w / v) (Patent Document 1).
[0005] As described above, in recent years, development of eye drops that do not use benzalkonium chloride has been underway, and there is a tendency to avoid the use of benzalkonium chloride in aqueous compositions.
[0006] In addition, from the viewpoint of medication compliance, it is desirable to have fewer times of daily dosing. However, if the dosing frequency is reduced, there is a possibility that the effective concentration in the biological tissue cannot be maintained, thereby reducing the efficacy. In order to exert the efficacy, it is necessary to maintain the effective concentration in the biological tissue. In the case of eye drops, as methods for maintaining the effective concentration in the eye tissue, methods of increasing the concentration of the active ingredient, methods of using an absorption promoter, and methods of improving the retention in the eye tissue by combining a thickener, etc. are known.
[0007] For example, Patent Document 2 describes that the effect of prolonging the duration of action after administration is achieved by adding a β-blocker to an aqueous solution containing alginic acid and adjusting the pH to 6 to 8. Patent Document 3 also describes that the intraocular migration of a β-blocker is improved by adding a sugar alcohol to the β-blocker.
[0008] On the other hand, it has been reported that a topically administrable aqueous solution containing epinastine can inhibit the influx of neutrophils and eosinophils into the tissues of the conjunctiva of the eyeball and the nasal mucosa, thereby reducing or preventing the occurrence of delayed phase reactions, and a certain amount of benzalkonium chloride is added to the aqueous solution as a preservative (Patent Document 4).
[0009] There is no report that a quaternary ammonium compound such as benzalkonium chloride is added to an aqueous composition containing epinastine or a salt thereof to enhance migration of epinastine or a salt thereof into ocular tissues and thereby maintain an effective concentration in ocular tissues.
[0010] Prior art literature
[0011] Patent Literature
[0012] Patent Document 1: Japanese Patent No. 6134853
[0013] Patent Document 2: Japanese Patent Publication No. 2002-511430
[0014] Patent Document 3: International Publication No. 2012 / 026609
[0015] Patent Document 4: Japanese Patent Application No. 2003-514021
[0016] Non-patent literature
[0017] Non-patent document 1: Alesion (注册商标) Eye drops 0.05% instructions Summary of the invention
[0018] Problems to be solved by the invention
[0019] Therefore, in order to achieve excellent drug efficacy, it is very useful to improve the migration of active ingredients to tissues, especially ocular tissues. It is an interesting subject to provide an aqueous composition containing epinastine or a salt thereof as an active ingredient and having improved migration to tissues, especially ocular tissues.
[0020] Means for solving problems
[0021] The inventors of the present application have conducted intensive studies on aqueous compositions containing epinastine or a salt thereof and have found that when an aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound adjusted to a specific content is administered to the eye by eye drops, the migration of epinastine to ocular tissues is improved, thereby completing the present invention.
[0022] Specifically, the present invention provides the following solutions.
[0023] (1) An aqueous composition comprising epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the quaternary ammonium compound to epinastine or a salt thereof is 0.1 parts by weight or less per 1 part by weight of epinastine or a salt thereof.
[0024] (2) The aqueous composition according to (1), wherein epinastine or a salt thereof is epinastine hydrochloride.
[0025] (3) The aqueous composition according to (1) or (2), wherein the concentration of epinastine or a salt thereof is 0.01 to 5% (w / v).
[0026] (4) The aqueous composition according to (1) or (2), wherein the concentration of epinastine or a salt thereof is 0.05% (w / v) or more.
[0027] (5) The aqueous composition according to any one of (1) to (4), wherein the concentration of epinastine or a salt thereof is 0.1% (w / v).
[0028] (6) The aqueous composition according to any one of (1) to (5), wherein the quaternary ammonium compound is at least one selected from the group consisting of benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, and polychlorinium chloride.
[0029] (7) The aqueous composition according to any one of (1) to (6), wherein the quaternary ammonium compound is benzalkonium chloride.
[0030] (8) The aqueous composition according to any one of (1) to (7), wherein the content ratio of the quaternary ammonium compound to epinastine or its salt is 0.05 parts by weight or less per 1 part by weight of the content of epinastine or its salt.
[0031] (9) The aqueous composition according to any one of (1) to (8), which is for ophthalmic use.
[0032] (10) The aqueous composition according to any one of (1) to (9), which is an eye drop.
[0033] (11) A method for enhancing the migration of epinastine or a salt thereof to ocular tissues by adding a quaternary ammonium compound to an aqueous composition containing epinastine or a salt thereof as an active ingredient.
[0034] (12) The method according to (11), wherein the quaternary ammonium compound is one or more selected from the group consisting of benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride and polychloridium chloride.
[0035] (13) The method according to (11) or (12), wherein the quaternary ammonium compound is benzalkonium chloride.
[0036] (14) An eye drop comprising benzalkonium chloride and epinastine hydrochloride at a concentration of 0.1% (w / v), wherein the content ratio of benzalkonium chloride to epinastine hydrochloride is 0.0001 parts by weight or more and less than 0.1 parts by weight per 1 part by weight of epinastine hydrochloride.
[0037] It should be noted that two or more of the above-mentioned structures (1) to (14) can be arbitrarily selected and combined.
[0038] In addition, the present invention also provides the following solutions.
[0039] (15) A method for treating an allergic disease, comprising administering a therapeutically effective amount of the aqueous composition according to any one of (1) to (10) to a patient in need of treatment.
[0040] (16) The aqueous composition according to any one of (1) to (10), which is used for treating an allergic disease.
[0041] (17) Use of the aqueous composition according to any one of (1) to (10) for producing a medicament for treating an allergic disease.
[0042] Effects of the Invention
[0043] The present invention provides an aqueous composition which can enhance the migration of epinastine or its salt to ocular tissues by adding a quaternary ammonium compound to an aqueous composition containing epinastine or its salt, thereby providing excellent drug efficacy. DETAILED DESCRIPTION
[0044] Hereinafter, the present invention will be described in detail.
[0045] In the present invention, "epinastin" refers to a compound represented by the chemical name (±)-3-Amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine, and also refers to a compound represented by the following formula:
[0046] [Chemical formula 1]
[0047]
[0048] Epinastine contained in the aqueous composition of the present invention may be a racemic form or an optical isomer.
[0049] Epinastine contained in the aqueous composition of the present invention may be in the form of a salt, and there are no particular limitations as long as it is a pharmaceutically acceptable salt. Examples of the salt include salts with inorganic acids and salts with organic acids.
[0050] Examples of the salt with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
[0051] Examples of the salt with an organic acid include salts with acetic acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptonic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, alanine, lactic acid, hippuric acid, 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid, oleic acid, gallic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfate, dimethyl sulfate, naphthalenesulfonic acid, and sulfosalicylic acid.
[0052] As the salt of epinastine, monohydrochloride (epinastine hydrochloride) is particularly preferred.
[0053] Epinastine or a salt thereof contained in the aqueous composition of the present invention may be in the form of a hydrate or a solvate.
[0054] In the aqueous composition of the present invention, the content of epinastine or its salt is preferably 0.01% (w / v) or more, more preferably 0.05% (w / v) or more, and even more preferably 0.1% (w / v) or more, and the upper limit thereof is any concentration permitted as an ophthalmic preparation, for example, 5% (w / v). The content of epinastine or its salt is preferably 0.01 to 5% (w / v), more preferably 0.05 to 1% (w / v), even more preferably 0.05 to 0.2% (w / v), and particularly preferably 0.05 to 0.1% (w / v). For example, the content is 0.1% (w / v).
[0055] It should be noted that, in the present invention, "% (w / v)" refers to the mass (g) of the target component contained in 100 mL of the aqueous composition of the present invention. In the present invention, when a salt of epinastine is contained, the value is the content of the salt of epinastine. In addition, in the present invention, when epinastine or its salt is combined in the form of a hydrate or a solvate, the value is the content of the hydrate or solvate of epinastine or its salt. Hereinafter, unless otherwise specified, it has the same meaning.
[0056] In the present invention, "quaternary ammonium compound" refers to a salt formed by a quaternary ammonium cation and other anions, also called a quaternary ammonium salt.
[0057] In the aqueous composition of the present invention, examples of the quaternary ammonium compound contained include benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, polychlorinium chloride, cetylpyridinium chloride, benzalkonium bromide, benzethonium bromide, methylbenzethonium bromide, cetrimide, etc., preferably benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, polychlorinium chloride, and more preferably benzalkonium chloride.
[0058] In the aqueous composition of the present invention, the quaternary ammonium compound also has a role as an additive for pharmaceuticals, such as a preservative, surfactant, stabilizer, isotonic agent, buffer, etc. Therefore, the quaternary ammonium compound can also be used as an additive for pharmaceuticals.
[0059] In the aqueous composition of the present invention, the quaternary ammonium compound may be used alone or in combination of two or more.
[0060] In the aqueous composition of the present invention, the content of the quaternary ammonium compound can be appropriately adjusted according to the type, for example, 0.0001 to 1% (w / v), preferably 0.0001 to 0.1% (w / v), more preferably 0.0001 to 0.01% (w / v), and further preferably 0.0001 to 0.005% (w / v). For example, when the quaternary ammonium compound is benzalkonium chloride, the possibility of causing corneal epithelial damage increases if the exposure amount increases, so the upper limit of the content is preferably 0.01% (w / v) or less or less than 0.01% (w / v), and more preferably 0.005% (w / v). The lower limit of the content is preferably 0.0001% (w / v) or more, more preferably 0.001% (w / v) or more, and further preferably 0.003% (w / v) or more. More specifically, the content is preferably 0.0001 to 0.01% (w / v), more preferably 0.001 to 0.005% (w / v), further preferably 0.001 to 0.003% (w / v) or 0.003 to 0.005% (w / v).
[0061] In the aqueous composition of the present invention, the content ratio of the quaternary ammonium compound can be appropriately adjusted according to the type. For example, the upper limit of the content ratio is 0.1 weight part or less or less than 0.1 weight part, preferably 0.05 weight part or less, relative to 1 weight part of the content of epinastine or its salt. The lower limit of the content ratio is 0.0001 weight part or more, preferably 0.001 weight part or more, more preferably 0.003 weight part or more, 0.005 weight part or more, or 0.01 weight part or more, relative to 1 weight part of the content of epinastine or its salt. In more detail, the content ratio is 0.0001-0.1 weight part, preferably 0.001-0.1 weight part, more preferably 0.003-0.1 weight part, further preferably 0.005-0.05 weight part, and particularly preferably 0.01-0.05 weight part. For example, when the quaternary ammonium compound is benzalkonium chloride, the possibility of causing corneal epithelial damage increases if the exposure amount increases, so the content ratio is 0.1 weight part or less, preferably 0.05 weight part or less, or 0.03 weight part or less, relative to 1 weight part of epinastine or its salt. More specifically, the content ratio is 0.0001 to 0.1 weight part, preferably 0.001 to 0.1 weight part, more preferably 0.003 to 0.1 weight part, further preferably 0.005 to 0.05 weight part, particularly preferably 0.01 to 0.05 weight part, and particularly preferably 0.03 to 0.05 weight part.
[0062] The aqueous composition containing epinastine or its salt at a concentration above a certain value can obtain a sufficient antiseptic effect without substantially containing a preservative or a component having an antiseptic effect. In the aqueous composition of the present invention, for example, when the quaternary ammonium compound is benzalkonium chloride commonly used as a preservative, the content of benzalkonium chloride may be less than the amount that can exert the effect of the present invention, or may contain the amount that can exert the effect of the present invention. On the other hand, as long as the effect of the present invention is exerted, the content of benzalkonium chloride can be the amount that can exert the effect of the preservative.
[0063] In the present invention, examples of ocular tissues include conjunctiva, cornea, tears, aqueous humor, anterior chamber, etc. When the aqueous composition of the present invention is administered to the eye, the amount of epinastine or a salt thereof migrating to the ocular tissue can be increased (or also referred to as enhanced).
[0064] In the present invention, "aqueous composition" refers to a composition containing water. The content of water contained in the aqueous composition of the present invention is not particularly limited, but is preferably 10% (w / v) or more, more preferably 30% (w / v) or more, and further preferably 50% (w / v) or more, relative to the total weight of the aqueous composition. In particular, it is preferably 70% (w / v) or more, more preferably 90% (w / v) or more, and further preferably 95% (w / v) or more.
[0065] In the present invention, "patient" is not limited to humans, but also refers to other animals, such as dogs, cats, horses, etc. The patient is preferably a mammal, more preferably a human. In the present invention, "therapeutically effective amount" refers to an amount that brings about a therapeutic effect on a disease and its symptoms, or an amount that brings about a delay in the progression of a disease and its symptoms, etc., compared with an untreated subject.
[0066] The aqueous composition of the present invention may contain pharmaceutical additives as needed, such as buffers, thickeners, surfactants, isotonic agents, stabilizers, preservatives, antioxidants, pH adjusters, etc. These may be used alone or in combination of two or more, and appropriate amounts may be used.
[0067] When a buffer is added to the aqueous composition of the present invention, the buffer can be appropriately added with a buffer that can be used as an additive for pharmaceuticals, and examples thereof include phosphoric acid or its salts, boric acid or its salts, carbonic acid or its salts, citric acid or its salts, acetic acid or its salts, tartaric acid or its salts, ε-aminocaproic acid or its salts, glutamic acid or its salts, and organic amines. Hydrates or solvates of these may also be mentioned.
[0068] Examples of the phosphoric acid or its salt include phosphoric acid, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate (hereinafter also referred to as sodium hydrogen phosphate), potassium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate. Hydrates of these may also be used.
[0069] Examples of the boric acid or a salt thereof include boric acid, sodium borate (borax), potassium borate, and the like, and hydrates of these may also be used.
[0070] Examples of carbonic acid or its salt include carbonic acid, sodium carbonate, sodium hydrogen carbonate, and the like. Hydrates of these may also be used.
[0071] Examples of citric acid or a salt thereof include citric acid, monosodium citrate, disodium citrate, trisodium citrate, and the like. Hydrates of these may also be used.
[0072] Examples of acetic acid or a salt thereof include acetic acid and sodium acetate, and hydrates of these may also be used.
[0073] Examples of tartaric acid or a salt thereof include tartaric acid, monosodium tartrate, disodium tartrate, and the like, and hydrates of these may also be used.
[0074] Examples of the ε-aminocaproic acid or a salt thereof include ε-aminocaproic acid, sodium ε-aminocaproate, ε-aminocaproic acid hydrochloride, and the like. Hydrates of these may also be used.
[0075] Examples of glutamic acid or a salt thereof include glutamic acid, monosodium glutamate, disodium glutamate, glutamic acid hydrochloride, and the like. Hydrates of these may also be used.
[0076] Examples of the organic amine include tromethamine, and hydrates of these amines may also be used.
[0077] When a buffer is added to the aqueous composition of the present invention, the content of the buffer can be appropriately adjusted depending on the type of the buffer, etc., and is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), further preferably 0.1 to 5% (w / v), and particularly preferably 0.1 to 2% (w / v).
[0078] When a buffer is added to the aqueous composition of the present invention, the buffer may be used alone or in combination of two or more.
[0079] When a thickener is added to the aqueous composition of the present invention, a thickener that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, cellulose acetate phthalate, polyvinyl pyrrolidone, polyvinyl alcohol, carboxyvinyl polymer, polyethylene glycol, sodium hyaluronate, and the like.
[0080] When a thickener is added to the aqueous composition of the present invention, the content of the thickener can be appropriately adjusted depending on the type of the thickener, etc., and is preferably 0.001 to 5% (w / v), more preferably 0.01 to 3% (w / v), and even more preferably 0.1 to 2% (w / v).
[0081] When a thickener is added to the aqueous composition of the present invention, the thickener may be used alone or in combination of two or more.
[0082] When a surfactant is added to the aqueous composition of the present invention, a surfactant that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include cationic surfactants, anionic surfactants, and nonionic surfactants.
[0083] Examples of the cationic surfactant include alkylamine salts, alkylamine polyoxyethylene adducts, fatty acid triethanolamine monoester salts, acylaminoethyldiethylamine salts, fatty acid polyamine condensates, alkyl imidazolines, 1-acylaminoethyl-2-alkyl imidazolines, 1-hydroxyethyl-2-alkyl imidazolines, etc. It should be noted that quaternary ammonium cations such as benzalkonium chloride have the properties of cationic surfactants, but these are not included in the cationic surfactants in the present invention.
[0084] Examples of the anionic surfactant include phospholipids such as lecithin.
[0085] Examples of the nonionic surfactant include polyoxyethylene fatty acid esters such as polyoxyethylene 40 stearate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate, and polysorbate 65; polyoxyethylene hydrogenated castor oils such as polyoxyethylene 10 hydrogenated castor oil, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene 50 hydrogenated castor oil, and polyoxyethylene 60 hydrogenated castor oil; and polyoxyethylene 5 castor oil and polyoxyethylene 9 castor oil. , polyoxyethylene castor oils such as polyoxyethylene 15 castor oil, polyoxyethylene 35 castor oil, and polyoxyethylene 40 castor oil; polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (196) polyoxypropylene (67) glycol, and polyoxyethylene (20) polyoxypropylene (20) glycol; sucrose fatty acid esters such as sucrose stearate; tocopherol polyethylene glycol 1000 succinate (vitamin E TPGS), etc.
[0086] When a surfactant is added to the aqueous composition of the present invention, the content of the surfactant can be appropriately adjusted depending on the type of the surfactant, etc., and is preferably 0.01 to 1% (w / v), more preferably 0.05 to 0.5% (w / v), and further preferably 0.05 to 0.2% (w / v).
[0087] When a surfactant is added to the aqueous composition of the present invention, the surfactant may be used alone or in combination of two or more.
[0088] When an isotonic agent is added to the aqueous composition of the present invention, an isotonic agent that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include ionic isotonic agents and nonionic isotonic agents.
[0089] Examples of the ionic isotonic agent include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride.
[0090] Examples of the nonionic isotonic agent include glycerin, propylene glycol, polyethylene glycol, sorbitol, mannitol, trehalose, maltose, sucrose, and xylitol.
[0091] When an isotonic agent is added to the aqueous composition of the present invention, the content of the isotonic agent can be appropriately adjusted depending on the type of the isotonic agent, etc., and is preferably 0.001 to 10% (w / v), more preferably 0.01 to 5% (w / v), further preferably 0.1 to 3% (w / v), and particularly preferably 0.2 to 1% (w / v).
[0092] When an isotonic agent is added to the aqueous composition of the present invention, the isotonic agent may be used alone or in combination of two or more.
[0093] When a stabilizer is added to the aqueous composition of the present invention, a stabilizer that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include ethylenediaminetetraacetic acid or a salt thereof, cyclodextrin, and sodium thiosulfate.
[0094] Examples of ethylenediaminetetraacetic acid or a salt thereof include ethylenediaminetetraacetic acid, monosodium ethylenediaminetetraacetate, disodium ethylenediaminetetraacetate (hereinafter also referred to as sodium ethylenediaminetetraacetate), trisodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate, and the like. Hydrates of these may also be used.
[0095] When a stabilizer is added to the aqueous composition of the present invention, the content of the stabilizer can be appropriately adjusted depending on the type of the stabilizer, etc., and is preferably 0.001 to 5% (w / v), more preferably 0.01 to 3% (w / v), and further preferably 0.01 to 1% (w / v).
[0096] When a stabilizer is added to the aqueous composition of the present invention, the stabilizer may be used alone or in combination of two or more.
[0097] When a preservative is added to the aqueous composition of the present invention, a preservative that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include chlorhexidine gluconate, chlorhexidine hydrochloride, methylparaben, propylparaben, sodium chlorite, and chlorobutanol.
[0098] When a preservative is added to the aqueous composition of the present invention, the content of the preservative can be appropriately adjusted depending on the type of the preservative, etc., and may be an amount that does not adversely affect safety, and is preferably 0.0001 to 0.1% (w / v), more preferably 0.001 to 0.05% (w / v).
[0099] When a preservative is added to the aqueous composition of the present invention, the preservative may be used alone or in combination of two or more.
[0100] When an antioxidant is added to the aqueous composition of the present invention, an antioxidant that can be used as an additive for pharmaceuticals can be appropriately added, and examples thereof include ascorbic acid, tocopherol, butylated hydroxytoluene, sodium sulfite, and the like.
[0101] When an antioxidant is added to the aqueous composition of the present invention, the content of the antioxidant can be appropriately adjusted depending on the type of the antioxidant, etc., and is preferably 0.001 to 5% (w / v), more preferably 0.01 to 3% (w / v), and further preferably 0.1 to 2% (w / v).
[0102] When an antioxidant is added to the aqueous composition of the present invention, the antioxidant may be used alone or in combination of two or more.
[0103] When a pH adjuster is added to the aqueous composition of the present invention, the pH adjuster can be appropriately added with a pH adjuster that can be used as an additive for pharmaceuticals, such as an acid or a base. Examples of the acid include hydrochloric acid and phosphoric acid, and examples of the base include sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, and the like.
[0104] The pH of the aqueous composition of the present invention may be within the range acceptable for pharmaceuticals, for example, 4.0 to 8.5 or 4.0 to 8.0, preferably 6.0 to 8.0, more preferably 6.5 to 7.5. A pH of 6.7 to 7.3 is particularly preferred, and 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, or 7.3 is even more preferred.
[0105] The osmotic pressure ratio of the aqueous composition of the present invention may be within a range acceptable as a pharmaceutical, and is, for example, 0.5 to 2.0, preferably 0.7 to 1.6, more preferably 0.8 to 1.4, and even more preferably 0.9 to 1.2.
[0106] The aqueous composition of the present invention is particularly preferably used as a medicine and is suitable for non-oral (e.g., topical) administration. As the non-oral administration route of the aqueous composition of the present invention, there can be mentioned local administration routes permitted as pharmaceuticals, such as local administration to the eye (e.g., eye drops), nasal drops (transnasal) administration, local administration to the ear (e.g., ear drops), inhalation administration, spray administration, transdermal administration, administration on the skin, injection administration, etc. It is preferably administered locally to the eye. In addition, the aqueous composition of the present invention can also be administered orally.
[0107] The aqueous composition of the present invention can be used as an ophthalmic preparation, an otolaryngological preparation, an inhalation preparation, and a percutaneous absorption preparation, and its dosage form is not particularly limited as long as it can be used as a pharmaceutical. As dosage form, for example, oral administration agents such as liquids and suspensions, eye drops, nose drops, ear drops, inhalants, (inhalation powders, inhalation liquids, inhalation aerosols), ointments, creams, gels, percutaneous absorption preparations, patches (patches, papules), external liquids (lotions, liniments), external solid preparations (external powders), sprays (spray pumps, external aerosols), injections (infusions, implanted injections, continuous injections) and other local administration agents. Preferably, eye drops, ophthalmic percutaneous absorption preparations or ophthalmic injections, more preferably eye drops. These can be manufactured according to the usual methods in the technical field.
[0108] The aqueous composition of the present invention may be a composition in which all components are dissolved or partially suspended, or in the form of an emulsion or a semisolid. The aqueous composition of the present invention is more preferably a solution in which all components are dissolved, and most preferably an aqueous solution. For example, as long as it is for ophthalmic use, eye drops (eye drops) are particularly preferred.
[0109] When the aqueous composition of the present invention is an emulsion, it can be an oil-in-water emulsion (an emulsion with an aqueous phase as a continuous phase and composed of an aqueous phase and dispersed oily droplets) or an oil-in-water emulsion (an emulsion with an oil phase as a continuous phase and composed of oil and dispersed aqueous droplets).
[0110] When the aqueous composition of the present invention is used as an ophthalmic preparation, it is particularly useful as a therapeutic agent for allergic conjunctivitis. In addition, the aqueous composition of the present invention may contain a pharmaceutical active ingredient other than epinastine or its salt, such as an active ingredient used in other eye drops, unless otherwise specified.
[0111] When the aqueous composition of the present invention is administered to the eye as an eye drop, there is no particular limitation on the dosage as long as the desired medicinal effect is sufficiently achieved, and the eye drop can be one drop at a time, 1 to 10 times a day, preferably 1 to 6 times a day, more preferably 2 to 4 times a day, further preferably 2 times a day or 4 times a day, and particularly preferably 2 times a day.
[0112] When the aqueous composition of the present invention is used as eye drops, it can be contained in any container in a multi-dose container, a disposable single-dose container or a PFMD (Preservative Free Multi Dose) container. It should be noted that the raw material of the container is not particularly limited, as long as it is a container of the eye drops commonly used, preferably a resin container, such as polyethylene (PE) system, polypropylene (PP) system, polyethylene terephthalate (PET) system, polybutylene terephthalate (PBT) system, polypropylene-polyethylene copolymer system, polyvinyl chloride system, acrylic acid system, polystyrene system, polycyclic olefin copolymer system, etc. can be used. In addition, when the material of the resin container is, for example, polyethylene, polyethylene is classified according to its density, and containers such as low-density polyethylene (LDPE) system, medium-density polyethylene (MDPE) system, and high-density polyethylene (HDPE) system can be used.
[0113] Example
[0114] Preparation examples and test examples are shown below, but these are for better understanding of the present invention and do not limit the scope of the present invention.
[0115] Preparation Examples
[0116] Representative formulation examples of the present invention are shown below. In the following formulation examples, the amount of each component is the content in 1 mL of the formulation.
[0117] Preparation Example 1
[0118]
[0119] Preparation Example 2
[0120]
[0121] Preparation Example 3
[0122]
[0123]
[0124] Preparation Example 4
[0125]
[0126] Preparation Example 5
[0127]
[0128] Test example
[0129] 1. Intraocular pharmacokinetic study
[0130] (1) Preparation of test preparation
[0131] Epinastine hydrochloride, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate hydrate were dissolved in water to give the concentrations shown in Table 1 below, and a pH adjuster (diluted hydrochloric acid and / or sodium hydroxide) and water were added to make the total amount 10 mL, followed by filtration sterilization to prepare the preparation of Example 1 (pH 7.0).
[0132] In addition, the preparations of Example 2 and Comparative Example 1 shown in Table 1 below were prepared in the same manner as the preparation of Example 1.
[0133] Table 1
[0134]
[0135] (2) Test methods
[0136] 50 μL of each test preparation was administered to the eyes of the rabbits at 15-minute intervals for a total of 3 times. The eyeballs were taken out after the sacrifice at 0.25 hours, 0.5 hours, 1 hour, 2 hours and 4 hours after the last eye drop. The epinastine concentration in the cornea and aqueous humor was measured at each time point, and the AUC (area under the plasma concentration-time curve) was calculated. It should be noted that AUC was calculated by using Phoenix WinNonlin (注册商标) The calculation is done using the sparse sampling analysis of V8.1.
[0137] (3) Experimental results and discussion
[0138] The test results are shown in Table 2. It should be noted that "Mean" in the table represents the mean value, "SE" represents the standard error, and "N" represents the number of samples, which are calculated by common statistical processing.
[0139] Table 2
[0140]
[0141] As shown in Table 2, Examples 1 and 2 containing benzalkonium chloride as a quaternary ammonium compound were confirmed to have greater amounts of epinastine migrated into the cornea and aqueous humor than Comparative Example 1 not containing benzalkonium chloride. Therefore, it was shown that the aqueous composition of the present invention significantly improves migration into ocular tissues.
[0142] Industrial Applicability
[0143] The present invention provides an aqueous composition comprising epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the quaternary ammonium compound to epinastine or a salt thereof is 0.1 parts by weight or less per 1 part by weight of epinastine or a salt thereof.
Claims
1. Use of a quaternary ammonium compound for improving the migration of epinastine or its salt to ocular tissue in the preparation of an eye drop containing only epinastine or its salt, a quaternary ammonium compound, a buffer, an ionic isotonic agent and a pH regulator, in, The concentration of epinastine or its salt is 0.1% (w / v), The content ratio of the quaternary ammonium compound to epinastine or its salt is 0.01 to 0.05 parts by weight per 1 part by weight of the content of epinastine or its salt.
2. The use according to claim 1, wherein Epinastine or its salt is epinastine hydrochloride.
3. The use according to claim 1, wherein The quaternary ammonium compound is one or more selected from the group consisting of benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, and polychlorinium chloride.
4. The use according to claim 1, wherein The quaternary ammonium compound is benzalkonium chloride.
5. The use according to claim 1, wherein The content ratio of the quaternary ammonium compound to epinastine or its salt is 0.03 to 0.05 parts by weight per 1 part by weight of the content of epinastine or its salt.
